EMP-01 demonstrated a large, clinically meaningful reduction in patient-reported SAD symptoms at Day 43: placebo-adjusted LSMD -11.5 points ...
NEW ORLEANS -- Low-dose cariprazine (Vraylar) was associated with reductions in anxiety for patients with major depressive disorder (MDD), and the potential adjunctive therapy for this population also ...
Investigators assessed the safety and efficacy of lumateperone for the treatment of bipolar I and II disorders in patients experiencing major depressive episodes. Lumateperone was found, in a phase 3, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results